Gene: ALK

238
CD246|NBLST3
ALK receptor tyrosine kinase
protein-coding
2p23.2-p23.1
Ensembl:ENSG00000171094 MIM:105590 Vega:OTTHUMG00000152034 UniprotKB:Q9UM73
NG_009445.1
PubMed|SNP Mapped
CD|ND|AD
229   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.386e-2 (AD)  1.356e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs4520995chr2:29895520 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)
rs12473275chr2:29562915 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)
rs10193521chr2:29562813 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)
rs7592571chr2:29545028 (GRCh38.p7)C>A / C>Talcohol dependenceSNV(Single Nucleotide Variation)
rs12467802chr2:29524308 (GRCh38.p7)C>G / C>Talcohol dependenceSNV(Single Nucleotide Variation)
rs7580476chr2:29460692 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)
rs12617579chr2:29266754 (GRCh38.p7)C>Tnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg12252328chr2:29512828ALKGene body1.825e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
LGI20.734
AFAP10.722
KIAA12110.694
AMOTL10.693
DAB10.664
SH3RF30.64
PCDHGC40.634
MAFB0.628
NPR30.626
VTI1A0.625

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ACOT6-0.296
OR4F5-0.296
KIF19-0.295
RHBDL2-0.288
ABHD1-0.283
SLC14A1-0.279
TPPP2-0.274
IZUMO4-0.272
APOA1-0.27
NRN1L-0.27

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00171ATPSmall Molecule56-65-5Investigational|NutraceuticalTarget
DB08865CrizotinibSmall Molecule877399-52-5ApprovedTarget
DB09063CeritinibSmall Molecule1032900-25-6ApprovedTarget
DB11363AlectinibSmall Molecule-Approved|InvestigationalTarget
DB12267BrigatinibSmall Molecule1197953-54-0Approved|InvestigationalTarget
ID Drug Name Action PubMed
C44865917-(dimethylaminoethylamino)-17-demethoxygeldanamycin17-(dimethylaminoethylamino)-17-demethoxygeldanamycin results in decreased stability of ALK protein mutant form22912387
C0549192,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ALK mRNA"19422813
C0268052,4-diaminopyridine"2,4-diaminopyridine analog binds to and results in decreased activity of ALK protein"22564207
C0172052,4-diaminopyrimidine"2,4-diaminopyrimidine analog results in decreased phosphorylation of ALK protein mutant form"20979473
C0172052,4-diaminopyrimidine"ALK gene SNP inhibits the reaction [2,4-diaminopyrimidine analog results in decreased phosphorylation of ALK protein mutant form]"20979473|2097947
C0172052,4-diaminopyrimidine"ALK gene SNP results in decreased susceptibility to 2,4-diaminopyrimidine analog"20979473
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of ALK mRNA"28973690
C5585299-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one"ALK protein mutant form results in decreased susceptibility to 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one"22789543
C5622359-ethyl-6,6-dimethyl-8-(4-oxetan-3-ylpiperazin-1-yl)-11-oxo-6,11-dihydro-5H-benzo(b)carbazole-3-carbonitrile"9-ethyl-6,6-dimethyl-8-(4-oxetan-3-ylpiperazin-1-yl)-11-oxo-6,11-dihydro-5H-benzo(b)carbazole-3-carbonitrile results in decreased activity of ALK protein"21823617
D000111AcetylcysteineAcetylcysteine affects the phosphorylation of and affects the activity of ALK protein mutant form19503098
D000255Adenosine TriphosphateALK protein binds to Adenosine Triphosphate22072639
D000255Adenosine TriphosphateALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]22072639
D000255Adenosine Triphosphate[ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib22072639
D000452Aldrin"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ALK mRNA"19422813
D000452Aldrin[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA28263720
D000535Aluminum[APP protein modified form binds to Aluminum] which results in decreased expression of ALK mRNA21298039
D000638AmiodaroneAmiodarone results in increased expression of ALK mRNA19774075
D000643Ammonium ChlorideAmmonium Chloride affects the expression of ALK mRNA16483693
D001151ArsenicArsenic affects the methylation of ALK gene25304211
D001280AtrazineAtrazine results in decreased expression of ALK mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of ALK mRNA22300585
C006780bisphenol Abisphenol A results in decreased expression of ALK mRNA25181051
D004390ChlorpyrifosChlorpyrifos results in increased expression of ALK mRNA20350560
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ALK gene20938992
C551994crizotinibcrizotinib results in decreased activity of ALK protein mutant form21838707
C551994crizotinibALK gene mutant form results in decreased susceptibility to crizotinib22277784
C551994crizotinibALK gene SNP inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein mutant form]20979473|2097947
C551994crizotinibALK gene SNP results in decreased susceptibility to crizotinib20979473
C551994crizotinibALK protein mutant form inhibits the reaction [crizotinib binds to and results in decreased activity of ALK protein]22659414
C551994crizotinibALK protein mutant form inhibits the reaction [crizotinib results in decreased activity of ALK protein]21030459
C551994crizotinibALK protein mutant form inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]21948233
C551994crizotinib[ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib22072639
C551994crizotinibALK protein mutant form results in decreased susceptibility to crizotinib21791641|2194823
C551994crizotinibcrizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]23104988
C551994crizotinibcrizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]23104988
C551994crizotinibcrizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]22286764
C551994crizotinibcrizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein]22286764
C551994crizotinibcrizotinib results in decreased activity of ALK protein21030459|2181241
C551994crizotinibcrizotinib results in decreased activity of ALK protein mutant form21767331|2183870
C551994crizotinibcrizotinib results in decreased phosphorylation of ALK protein21502504|2194823
C551994crizotinibcrizotinib results in decreased phosphorylation of ALK protein mutant form20979473
C551994crizotinibcrizotinib results in decreased phosphorylation of and results in decreased activity of ALK protein mutant form23104988
C551994crizotinibcrizotinib results in decreased stability of ALK protein mutant form22912387
C551994crizotinibcrizotinib results in increased mutagenesis of ALK gene mutant form20979473|2150250
C551994crizotinib[crizotinib results in increased mutagenesis of ALK gene mutant form] which results in decreased susceptibility to crizotinib20979473|2150250
C551994crizotinibcrizotinib results in increased mutagenesis of ALK protein mutant form21030459
C551994crizotinib[crizotinib results in increased mutagenesis of ALK protein mutant form] which results in decreased susceptibility to crizotinib21030459
C551994crizotinib[crizotinib results in increased mutagenesis of ALK protein mutant form] which results in increased activity of ALK protein21030459
C551994crizotinib[Ethylnitrosourea results in increased mutagenesis of ALK protein] inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]22034911
C551994crizotinib[Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to crizotinib22034911
C551994crizotinibcrizotinib results in decreased activity of ALK protein mutant form21838707
C551994crizotinibcrizotinib binds to ALK protein21812414
C551994crizotinibcrizotinib results in decreased activity of ALK protein21823617
D003634DDT[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA28263720
D013759DronabinolALK mutant form promotes the reaction [Dronabinol results in decreased phosphorylation of NUPR1 protein]21233844
D013759DronabinolALK mutant form promotes the reaction [Dronabinol results in increased expression of NUPR1 mRNA]21233844
D013759DronabinolALK mutant form promotes the reaction [Dronabinol results in increased expression of TRIB3 mRNA]21233844
D013759DronabinolALK results in decreased susceptibility to Dronabinol21233844
D013759Dronabinol[NVP-TAE684 results in decreased phosphorylation of ALK protein] which results in increased susceptibility to Dronabinol21233844
D003632Dichlorodiphenyldichloroethane"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ALK mRNA"19422813
D003632Dichlorodiphenyldichloroethane[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA28263720
D003633Dichlorodiphenyl Dichloroethylene"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ALK mRNA"19422813
D003633Dichlorodiphenyl Dichloroethylene[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA28263720
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of ALK mRNA26924002
D004026Dieldrin"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ALK mRNA"19422813
D004026Dieldrin[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA28263720
C024629dimethyl phthalatedimethyl phthalate affects the expression of ALK mRNA26924002
D004732Endrin[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA28263720
D005038EthylnitrosoureaEthylnitrosourea results in increased mutagenesis of ALK protein21948233|2203491
D005038Ethylnitrosourea[Ethylnitrosourea results in increased mutagenesis of ALK protein] inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]22034911
D005038Ethylnitrosourea[Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to crizotinib22034911
D005038Ethylnitrosourea[Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to NVP-TAE68422034911
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ALK gene20938992
D004397FonofosFonofos results in increased methylation of ALK promoter22847954
D006861Hydrogen PeroxideHydrogen Peroxide results in increased phosphorylation of ALK protein mutant form19503098
D001556Lindane[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA28263720
D009637MasoprocolMasoprocol affects the phosphorylation of and affects the activity of ALK protein mutant form19503098
D009637MasoprocolMasoprocol results in decreased activity of ALK protein19503098
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ALK gene20938992
C517284monomethyl phthalatemonomethyl phthalate affects the expression of ALK mRNA26924002
C562237N-(2-(2-(4-(4-(2-hydroxypropyl)piperazin-1-yl)-2-methoxyphenylamino)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)phenyl)-N-methylmethanesulfonamide"ALK protein modified form results in increased susceptibility to N-(2-(2-(4-(4-(2-hydroxypropyl)piperazin-1-yl)-2-methoxyphenylamino)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)phenyl)-N-methylmethanesulfonamide"21859094
C562237N-(2-(2-(4-(4-(2-hydroxypropyl)piperazin-1-yl)-2-methoxyphenylamino)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)phenyl)-N-methylmethanesulfonamide"[ALK protein modified form results in increased susceptibility to N-(2-(2-(4-(4-(2-hydroxypropyl)piperazin-1-yl)-2-methoxyphenylamino)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)phenyl)-N-methylmethanesulfonamide] which results in increased activity of CASP3 protein"21859094
C562237N-(2-(2-(4-(4-(2-hydroxypropyl)piperazin-1-yl)-2-methoxyphenylamino)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)phenyl)-N-methylmethanesulfonamide"[ALK protein modified form results in increased susceptibility to N-(2-(2-(4-(4-(2-hydroxypropyl)piperazin-1-yl)-2-methoxyphenylamino)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)phenyl)-N-methylmethanesulfonamide] which results in increased activity of CASP7 protein"21859094
C568507N-(2-(3-(3,5-bis(trifluoromethyl)phenyl)ureido)ethyl)glycyrrhetinamide"N-(2-(3-(3,5-bis(trifluoromethyl)phenyl)ureido)ethyl)glycyrrhetinamide results in decreased activity of ALK protein"21888390
C056614N-(3-phenoxycinnamyl)acetohydroxamic acidN-(3-phenoxycinnamyl)acetohydroxamic acid results in decreased activity of ALK protein19503098
C516714NVP-TAE684NVP-TAE684 results in decreased activity of ALK protein mutant form21838707
C516714NVP-TAE684ALK protein mutant form inhibits the reaction [NVP-TAE684 results in decreased phosphorylation of ALK protein]21948233
C516714NVP-TAE684ALK protein mutant form results in decreased susceptibility to NVP-TAE68421791641|2194823
C516714NVP-TAE684EGF protein inhibits the reaction [NVP-TAE684 results in decreased phosphorylation of ALK protein]22843788
C516714NVP-TAE684[Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to NVP-TAE68422034911
C516714NVP-TAE684HGF protein inhibits the reaction [NVP-TAE684 results in decreased phosphorylation of ALK protein]22553343
C516714NVP-TAE684NVP-TAE684 inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]22286764
C516714NVP-TAE684NVP-TAE684 inhibits the reaction [ALK protein results in increased expression of MYCN protein]22286764
C516714NVP-TAE684NVP-TAE684 results in decreased activity of ALK protein mutant form21030459|2183870
C516714NVP-TAE684NVP-TAE684 results in decreased phosphorylation of ALK protein21233844|2150250
C516714NVP-TAE684[NVP-TAE684 results in decreased phosphorylation of ALK protein] which results in increased susceptibility to Dronabinol21233844
C516714NVP-TAE684NVP-TAE684 results in decreased activity of ALK protein mutant form21838707
C009618O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate"O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in decreased expression of ALK mRNA"21673326
D010278ParathionParathion results in increased methylation of ALK promoter22847954
D000068437PemetrexedALK gene mutant form affects the susceptibility to Pemetrexed21336183
C551178PF-04254644PF-04254644 affects the activity of ALK protein20231546
D011441PropylthiouracilPropylthiouracil results in increased expression of ALK mRNA24780913
D019821Simvastatin[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA28263720
C017947sodium arsenitesodium arsenite affects the expression of ALK mRNA19590694
C112765tanespimycintanespimycin results in decreased activity of ALK protein mutant form21030459
C112765tanespimycintanespimycin results in decreased expression of ALK protein21502504
C112765tanespimycintanespimycin results in decreased expression of ALK protein modified form21502504
C012568terbufosterbufos results in increased methylation of ALK promoter22847954
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of ALK mRNA21570461|2637764
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of ALK mRNA19465110
D014212Tretinoin[Tretinoin co-treated with ALK gene mutant form] results in increased cleavage of CASP3 protein20576349
D014212TretinoinTretinoin results in decreased expression of ALK mRNA20576349
D014212TretinoinTretinoin results in decreased expression of ALK protein20576349
D014212TretinoinTretinoin results in increased expression of ALK mRNA23724009
C015559trimellitic anhydridetrimellitic anhydride results in increased expression of ALK mRNA19042947
D014638VanadatesVanadates analog results in increased phosphorylation of ALK protein mutant form19503098
D014639VanadiumVanadium results in decreased expression of ALK mRNA19000753
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of ALK gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004704NF-kappaB-inducing kinase activity-TAS19459784  
GO:0004709MAP kinase kinase kinase activity-IBA21873635  
GO:0004713protein tyrosine kinase activity-IBA21873635  
GO:0004713protein tyrosine kinase activity-IDA9174053  
GO:0004714transmembrane receptor protein tyrosine kinase activity-IBA21873635  
GO:0004714transmembrane receptor protein tyrosine kinase activity-IDA9174053  
GO:0004714transmembrane receptor protein tyrosine kinase activity-TAS19459784  
GO:0004888transmembrane signaling receptor activity-IBA21873635  
GO:0005515protein binding-IPI15680399  17681947  22939624  26418745  
GO:0005524ATP binding-IEA-  
GO:0031434mitogen-activated protein kinase kinase binding-IBA21873635  
GO:0042802identical protein binding-IPI25517749  
GO ID GO Term Qualifier Evidence PubMed
GO:0000187activation of MAPK activity-TAS19459784  
GO:0001934positive regulation of protein phosphorylation-IBA21873635  
GO:0007165signal transduction-TAS19459784  
GO:0007169transmembrane receptor protein tyrosine kinase signaling pathway-IEA-  
GO:0007275multicellular organism development-IBA21873635  
GO:0008283cell proliferation-TAS19459784  
GO:0009968negative regulation of signal transduction-IBA21873635  
GO:0016310phosphorylation-IDA9174053  
GO:0016310phosphorylation-TAS19459784  
GO:0018108peptidyl-tyrosine phosphorylation-IEA-  
GO:0021766hippocampus development-IEA-  
GO:0030154cell differentiation-IBA21873635  
GO:0030534adult behavior-IEA-  
GO:0033674positive regulation of kinase activity-IBA21873635  
GO:0036269swimming behavior-IEA-  
GO:0038061NIK/NF-kappaB signaling-IEA-  
GO:0042127regulation of cell proliferation-IEA-  
GO:0042981regulation of apoptotic process-TAS19459784  
GO:0043066negative regulation of apoptotic process-IBA21873635  
GO:0046777protein autophosphorylation-IDA9174053  
GO:0046777protein autophosphorylation-TAS19459784  
GO:0048666neuron development-TAS19459784  
GO:0051092positive regulation of NF-kappaB transcription factor activity-TAS19459784  
GO:0060159regulation of dopamine receptor signaling pathway-IEA-  
GO:0070374positive regulation of ERK1 and ERK2 cascade-IBA21873635  
GO:0090648response to environmental enrichment-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005622intracellular-IEA-  
GO:0005737cytoplasm-IBA21873635  
GO:0005886plasma membrane-IDA-  
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0005887integral component of plasma membrane-IDA9174053  
GO:0005887integral component of plasma membrane-TAS19459784  
GO:0032991protein-containing complex-IDA23382219  
GO:0043235receptor complex-IBA21873635  
GO:0070062extracellular exosome-HDA19056867  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28065467Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases. (2017 Jul)Rokutan-Kurata MClin Lung Cancer
26677401MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. (2015)Garajova IClin Epigenetics
26898615K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature. (2016 Mar)Mengoli MCLung Cancer
21703634A meta-analysis of two genome-wide association studies identifies 3 new loci for alcohol dependence. (2011 Nov)Wang KSJ Psychiatr Res
27064578Epidemiology of Lung Cancer in Korea: Recent Trends. (2016 Apr)Park JYTuberc Respir Dis (Seoul)
25966792Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients. (2015 Jun)Cui SMed Oncol
29199691New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer. (2017 Jan-Mar)Dubey APIndian J Cancer
27646887[Expression of ALK protein in 7 371 pulmonary adenocarcinoma samples, with analysis of clinicopathologic features]. (2016 Sep 8)Zhao RYZhonghua Bing Li Xue Za Zhi
25360721Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis. (2014)Wang YPLoS One
28860576PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. (2017 Aug 31)Zhang MSci Rep
24466154Ion channel gene expression in lung adenocarcinoma: potential role in prognosis and diagnosis. (2014)Ko JHPLoS One
25126481Establishment and characterization of a singaporean chinese lung adenocarcinoma cell line with four copies of the epidermal growth factor receptor gene. (2014 Aug 1)Choong MLBiores Open Access
28683775ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature. (2017 Jul 6)Mamesaya NBMC Cancer
22548013Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. (2012 Jan)Nguyen KSJ Oncol Pract
24959902Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. (2014)Fan LPLoS One
28468034[To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung]. (2017 May 8)Sun PLZhonghua Bing Li Xue Za Zhi
29610932EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib. (2018 May)Huang TCancer Chemother Pharmacol
24888607Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. (2014 Sep)Kim TJJ Surg Oncol
23661716Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? (2013 Oct)Ou SHJ Clin Pathol
24442099Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. (2014 Mar)Wang JJ Cancer Res Clin Oncol
28468033[Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma]. (2017 May 8)Hou LKZhonghua Bing Li Xue Za Zhi
27217997Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey. (2016)Sag SOSpringerplus
29151522Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib. (2018 Mar 1)Hayashi NIntern Med
20659620Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. (2010 Sep)Murakami SLung Cancer
29191580Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis. (2017 Oct)Wang ZLung Cancer
25773866Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. (2015 May)Tsai THLung Cancer
29167001[Association between the ALK Gene Status and the Efficacy of First-line Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma]. (2017 Nov 20)Chen MZhongguo Fei Ai Za Zhi
25349974PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. (2015 Jan 6)D'Incecco ABr J Cancer
23788756The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. (2013 Sep)Kim HRAnn Oncol
25695224Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases. (2015 Mar)Gleeson FCJ Thorac Oncol
28806935Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. (2017 Aug 15)Zhao LBMC Pulm Med
27438512Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer. (2018 Apr)Jia XAppl Immunohistochem Mol Morphol
26923333Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods. (2016 Feb 29)Shi XSci Rep
28373815Systemic treatment of non-small cell lung cancer brain metastases. (2016)Cedrych IContemp Oncol (Pozn)
28514931Lung cancer in never-smokers - what are the differences? (2017 Jul)Dias MActa Oncol
26893860Genetic alterations in lung adenocarcinoma with a micropapillary component. (2016 Feb)Furukawa MMol Clin Oncol
19671850Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. (2009 Aug 15)Rodig SJClin Cancer Res
22605530Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. (2012 Dec 1)Paik PKCancer
25745045No impact of passive smoke on the somatic profile of lung cancers in never-smokers. (2015 May)Couraud SEur Respir J
25567908Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. (2015 Aug 15)Drilon AClin Cancer Res
21178715Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion. (2011 Jan)Laack EJ Thorac Oncol
21420271[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]. (2011 Apr)Hadoux JPresse Med
23551194Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. (2013 Jun)Lindeman NIArch Pathol Lab Med
26601054Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. (2015)Rangachari DCancer Treat Commun
25833149Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. (2015)de Melo ACOncology
29631966MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. (2018 Mar 17)Reis HClin Lung Cancer
24850843FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. (2014 Aug 1)Wang RClin Cancer Res
27298405Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer. (2016 Aug 20)Rusthoven CGJ Clin Oncol
24477503Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer. (2014 Jun)Lee YGThromb Haemost
29661733Analysis of EML4-ALK rearrangement in non-small cell lung cancer in Argentina. (2018 Feb 26)Verzura MAnn Diagn Pathol
21655907Lung cancers unrelated to smoking: characterized by single oncogene addiction? (2011 Aug)Suda KInt J Clin Oncol
23802852Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients. (2014 Mar)McQuitty EArch Pathol Lab Med
25243942Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma. (2015 Jan)Jeong CJClin Nucl Med
24942490ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients. (2014 Nov)Tuononen KGenes Chromosomes Cancer
26202550Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. (2015 Dec)Zheng DAnn Surg Oncol
27467545Adipophilin expression in lung adenocarcinoma is associated with apocrine-like features and poor clinical prognosis: an immunohistochemical study of 328 cases. (2017 Jan)Fujimoto MHistopathology
28210129Targeted inhibition in tumors with ALK dependency. (2013)Kwak ELLung Cancer (Auckl)
25361983Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. (2015 Jan)Kobayashi YAnn Oncol
23738762Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. (2014 May)Hwang DHArch Pathol Lab Med
23877438CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. (2013 Oct)Matsuura SOncol Rep
29228652Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma in situ and minimally invasive adenocarcinoma of lung. (2017 Nov 17)Yu ROncotarget
27001591Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient. (2016 May 1)Presley CJJ Clin Oncol
27943404The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking. (2017 May)Skov BGHistopathology
24388371Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer. (2014 Jan)Kobayashi MRespir Investig
24362875Fishing for ALK with immunohistochemistry may predict response to crizotinib. (2013 Sep-Oct)Bavieri MTumori
27500967ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India. (2016 Oct)Bal AAPMIS
25180059Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples. (2014 Jun)Zhao CTransl Oncol
29744229ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib. (2018)Sagawa RCase Rep Oncol Med
27561692ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. (2016 Aug 25)Peretti URespir Res
23988776EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. (2014 Mar)Warth AEur Respir J
26705279[Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation]. (2015 Sep)Zhong SZhonghua Bing Li Xue Za Zhi
25267753How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis. (2014 Nov 10)Zwicker JIJ Clin Oncol
29656747Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. (2018 May)Fujimoto DLung Cancer
28285691Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics. (2017 Apr)Halpenny DFLung Cancer
23515407Characteristics of lung cancers harboring NRAS mutations. (2013 May 1)Ohashi KClin Cancer Res
25657019BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. (2015 May)Couraud SEur Respir J
26955281The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. (2016)Zheng DOnco Targets Ther
25557162Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells. (2015 Mar)Pareja FCancer Cytopathol
29449735ALK-positive adenocarcinoma of the lung expressing neuroendocrine markers and presenting as a "pituitary adenoma". (2017 Dec)Mengoli MCPathologica
22483782Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. (2012 Aug)Fukui TLung Cancer
25870798Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. (2015 Apr)Kohno TTransl Lung Cancer Res
26164066Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. (2015 Sep)Preusser MEur J Cancer
25582278EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity. (2015 Mar)Yang YLung Cancer
28685219Clinicopathological Significance of Micropapillary Pattern in Lung Adenocarcinoma. (2018 Jul)Pyo JSPathol Oncol Res
28676214DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. (2017 Aug)Takamochi KLung Cancer
20614325Solitary fibrous tumor of the larynx. (2008 Jun)Thompson LDHead Neck Pathol
25152623Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. (2014)Hu HOnco Targets Ther
24589437Prospective screening for ALK: clinical features and outcome according to ALK status. (2014 May)Fallet VEur J Cancer
29128428Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. (2018 Jan)Ferrara RJ Thorac Oncol
16819319Pseudosarcomatous myofibroblastic proliferations of the bladder: a clinicopathologic study of 42 cases. (2006 Jul)Harik LRAm J Surg Pathol
28050149Treatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective study. (2016 Dec)Kayaniyil SCurr Oncol
25288236Molecular alterations in non-small cell lung carcinomas of the young. (2014 Dec)VandenBussche CJHum Pathol
23552377Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. (2013 Jul)Lindeman NIJ Thorac Oncol
23932486Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. (2013 Oct)Yamaguchi NLung Cancer
29682332Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? (2018)Pinto JAESMO Open
24723496Cytomorphology of non-small cell lung carcinoma with anaplastic lymphoma kinase gene rearrangement. (2015 Jan)Toll ADDiagn Cytopathol
24346098Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation. (2014 Jan)Tufman ALJ Thorac Oncol
27766545From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer? (2016 Dec)D'Argento ECurr Treat Options Oncol
23928533[Detection of EML4-ALK fusion gene in non-small cell lung cancer and its clinicopathologic correlation]. (2013 Apr)Zhong SZhonghua Bing Li Xue Za Zhi
28433570Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry. (2017 Sep)Soo RAClin Lung Cancer
26350052Molecular Testing in Multiple Synchronous Lung Adenocarcinomas: Case Report and Literature Review. (2016 Feb)Rafael OCInt J Surg Pathol
27987580Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. (2016 Dec)Chapman AMLung Cancer
26392858ALK-rearranged squamous cell carcinoma of the lung. (2015 Sep)Takanashi YRespirol Case Rep
24729716Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. (2014)Li HOnco Targets Ther
28559820Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer. (2017 Jan-Apr)Yamasaki MCase Rep Oncol
25914136ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. (2015 Jun)Guerin ACancer Epidemiol
22768234Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. (2012)An SJPLoS One
23919423Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. (2013 Oct)Xia NExp Lung Res
27008586Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer. (2017 Jan)Bu SAnn Surg Oncol
27281559Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer. (2016 Dec 1)Wang EClin Cancer Res
28644837Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. (2017)Abernethy APPLoS One
25789627Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. (2015)Hsu KHPLoS One
21336183Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. (2011 Apr)Camidge DRJ Thorac Oncol
27086595Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases. (2016 May)Lee TJ Pathol Transl Med
29683890Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients. (2018 Apr 20)Tseng JSJ Immunother
27100677Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression. (2016)Sato KPLoS One
27262212Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. (2016 Aug)Noonan SAJ Thorac Oncol
24920890Pulmonary adenocarcinoma mutation profile in smokers with smoking-related interstitial fibrosis. (2014)Primiani AInt J Chron Obstruct Pulmon Dis
25855381Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. (2015 Jun 1)Saito MCancer Res
22317764Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. (2012 Apr 1)Zhang YClin Cancer Res
21562939Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features. (2011 Aug)Yano TInt J Clin Oncol
26623133Epithelioid inflammatory myofibroblastic sarcoma: a case report. (2015 Oct)Sarmiento DEJ Thorac Dis
29277178[Clinical Significance and Mechanism of PI3K p110beta Overexpression in Non-small Cell Lung Cancer]. (2017 Dec 20)Xiong YZhongguo Fei Ai Za Zhi
25862146PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. (2015 Jun)Chang YLLung Cancer
25588859Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report. (2015 May 26)Campos-Gomez SInt J Biol Markers
26767032Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma. (2014 Sep)Zhu JThorac Cancer
23856136[Prognosis related clinical and molecular factors in malignant pleural mesothelioma]. (2013 Mar)Wang YYZhonghua Jie He He Hu Xi Za Zhi
28513466Non-small cell lung cancer - mutations, targeted and combination therapy. (2017 May 17)Kutkowska JPostepy Hig Med Dosw (Online)
28423587The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC. (2017 Apr 4)Yang HOncotarget
27103824Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer. (2016)Wen MOnco Targets Ther
26253541Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement. (2015 Aug 8)Fu SChin J Cancer
27330767Anaplastic lymphoma kinase-positive squamous cell carcinoma of the lung: A case report. (2016 Jul)Yamamoto YMol Clin Oncol
26200269Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. (2015 Aug)Shim HSJ Thorac Oncol
22975805The transcriptional landscape and mutational profile of lung adenocarcinoma. (2012 Nov)Seo JSGenome Res
25407901Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset. (2014 Nov 18)Guo YBMC Cancer
29413057Tumor biomarker testing in non-small-cell lung cancer: A decade of change. (2018 Feb)VanderLaan PALung Cancer
28534101Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique. (2017 Dec)Nicos MClin Transl Oncol
27142166ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy. (2016 May 3)Incharoen PWorld J Surg Oncol
26739511Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening. (2016 Jan 7)Yang YSci Rep
22707299Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. (2012 Nov)Ren SCell Biochem Biophys
27646667[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement]. (2017 May)Caliez JRev Mal Respir
18166835EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. (2008 Jan)Inamura KJ Thorac Oncol
28104537Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >/=50% Expression in Lung Adenocarcinoma. (2017 May)Rangachari DJ Thorac Oncol
23664446EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report. (2013 Aug)Ali GLung Cancer
23677552[Gender-specific difference in lung cancer]. (2013 May)Serke MPneumologie
24755712Evidence that the lung Adenocarcinoma EML4-ALK fusion gene is not caused by exposure to secondhand tobacco smoke during childhood. (2014 Jul)Ryan BMCancer Epidemiol Biomarkers Prev
24828667Small-cell lung cancers in patients who never smoked cigarettes. (2014 Jun)Varghese AMJ Thorac Oncol
28494184Current status of research and treatment for non-small cell lung cancer in never-smoking females. (2017 Jun 3)Saito SCancer Biol Ther
21483012Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. (2011 May 20)Paik PKJ Clin Oncol
27188576Non-small-cell lung cancer. (2015 May 21)Gridelli CNat Rev Dis Primers
27635639Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. (2017 Nov 2)Song ZCancer Biol Ther
29123416Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer. (2017)Tufman AOnco Targets Ther
2135058Serum choline esterase and liver function among a group of organophosphorus pesticides sprayers in Egypt. (1990 Nov-Dec)Kamal AAJ Toxicol Clin Exp
29413048Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells? (2018 Feb)Zhou FLung Cancer
11931612GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND). (2002 Apr 11)Benedetti PJ Med Chem
28103968[Gene Expression and Clinical Characteristics of Molecular Targeted Therapy in Non-small Cell Lung Cancer Patients in Shandong]. (2017 Jan 20)Qiao XZhongguo Fei Ai Za Zhi
22736493Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. (2012 Oct)Shaozhang ZGenes Chromosomes Cancer
7466143[Early liver damage caused by alcohol]. (1980 Oct-Dec)Garca Vigil JLRev Gastroenterol Mex
15499043Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. (2005 Jan)Kerner AArterioscler Thromb Vasc Biol
28210164Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives. (2016)Leprieur EGLung Cancer (Auckl)
18242762EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. (2008 Aug)Shinmura KLung Cancer
27033383[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer]. (2016 Apr 8)Chen LFZhonghua Bing Li Xue Za Zhi
26536196Clinical Implications of Variant ALK FISH Rearrangement Patterns. (2015 Nov)Gao XJ Thorac Oncol
25113306US lung cancer trends by histologic type. (2014 Sep 15)Lewis DRCancer
25007143Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. (2014 Dec)Boland JMAm J Surg Pathol
23150706RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. (2012 Dec 10)Wang RJ Clin Oncol
23341890Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. (2013)Li YPLoS One
27470969PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? (2016 Sep 15)Gettinger SClin Cancer Res
25434695A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. (2014 Dec 1)Hong SSci Rep
26752591Anaplastic lymphoma kinase regulates binge-like drinking and dopamine receptor sensitivity in the ventral tegmental area. (2017 May)Dutton JW 3rdAddict Biol
27573756Crizotinib resistance: implications for therapeutic strategies. (2016 Sep)Dagogo-Jack IAnn Oncol
20130484Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. (2010 Apr)Ou SHJ Thorac Oncol
23098378Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. (2013 Jan)Li HLung Cancer
21062932Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. (2010 Nov 15)Camidge DRClin Cancer Res
26582178The performance of NLST screening criteria in Asian lung cancer patients. (2015 Nov 18)Kumar VBMC Cancer
26208325Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. (2015)Chatziandreou IPLoS One
27027665Gene aberrations for precision medicine against lung adenocarcinoma. (2016 Jun)Saito MCancer Sci
26788139EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer. (2015 Dec)Ren WOncol Lett
28280984Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. (2018 Jan)Saito MSurg Today
28118634Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement. (2017)Lin DOncol Res Treat
28024691Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches. (2017 Jan)Demidova ILung Cancer
23251849Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts. (2012 Dec)Suda KAging Dis
26273395Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements. (2015 Jul)Wu SThorac Cancer
21933749Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. (2011 Oct)Shaw ATLancet Oncol
26775573[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)]. (2016 Jan)Hamard CAnn Pathol
27793199Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China. (2016 Oct 28)Li XBMC Cancer
24279718Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. (2013 Nov 26)Rossing HHBMC Res Notes
22887466Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. (2013 Jan)Shaw ATAnn Oncol
29530732Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis. (2018 Feb 21)Petrelli FClin Lung Cancer
28210171Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer. (2016)Legius BLung Cancer (Auckl)
27655296Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia. (2016 Sep 21)Brcic LDiagn Pathol
28507205A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. (2017 Jul)Wang VEOncologist
22464348Lung cancer in never smokers--a review. (2012 Jun)Couraud SEur J Cancer
25922742Anaplastic lymphoma kinase-positive lung adenocarcinoma patient with development of sick sinus syndrome while on targeted treatment with crizotinib. (2015 Mar)Jiang HJ Thorac Dis
27799390Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases. (2016 Nov)Ruano-Ravina AEur Respir J
25706305Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis. (2015)Zhao FPLoS One
25738220Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. (2015 May)Sholl LMJ Thorac Oncol
23562183Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. (2013 Jul)Lindeman NIJ Mol Diagn
23052178EML4-ALK-positive non-small cell lung cancer in a patient treated with azathioprine for ulcerative colitis. (2012 Jul-Aug)Lazarev ITumori
26437441Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks. (2015 Sep 30)Seki YBiomolecules
27747151A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation. (2016)Imamura FRespir Med Case Rep
19234440EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. (2009 Apr)Inamura KMod Pathol
26762747Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. (2016 Jan)Michels SJ Thorac Oncol
23723294Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). (2013 Sep)Dearden SAnn Oncol
26888425Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients. (2016 May)Tian GFuture Oncol
28840008Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study. (2017 Jul)Zhang JJ Thorac Dis
28881815Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. (2017 Aug 8)Dugay FOncotarget
29799009Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients. (2018 May 24)Wang CNat Commun
23887156ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. (2013 Sep)Sholl LMAm J Surg Pathol
22980554[Cavitating nodules in a 40-year-old non-smoking woman: a very particular tumour]. (2012 Sep)Albahary MVRev Mal Respir
27446444Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia). (2016 Aug)Sanchez-Ares MOncol Lett
29764592[Analysis of the First Diagnosis Symptom and Its Influencing Factors in 500 Patients with Lung Cancer]. (2018 May 20)Zhang XZhongguo Fei Ai Za Zhi
26946429Dependence-induced ethanol drinking and GABA neurotransmission are altered in Alk deficient mice. (2016 Aug)Schweitzer PNeuropharmacology
19667264Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. (2009 Sep 10)Shaw ATJ Clin Oncol
20926401EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. (2010 Oct 15)Sakairi YClin Cancer Res
23439505Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history. (2013)Furukawa MActa Med Okayama
25327654[ALK protein expression and gene fusion in bronchoscopic specimens of lung adenocarcinoma]. (2014 Jul)Liang XZhonghua Zhong Liu Za Zhi
29137260Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma. (2017 Oct 10)Dong YOncotarget
28914263Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. (2018 Feb)Tang ZMod Pathol
29191596PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. (2017 Oct)Brody RLung Cancer
24643262Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? (2014 Apr)Ou SHPostgrad Med J
29312770Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung. (2017 Dec)Kalchiem-Dekel OJ Thorac Dis
27388008Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed. (2016 Jul 7)Park SBMC Cancer
25488863Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung. (2015 Feb)Qiong ZLung Cancer
24163741Molecular biology of lung cancer. (2013 Oct)Cooper WAJ Thorac Dis
27879019Screening for ALK abnormalities in central nervous system metastases of non-small-cell lung cancer. (2018 Jan)Nicos MBrain Pathol
24300132Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. (2014 Feb)Sun JMLung Cancer
26599269Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. (2015)Gautschi OOncol Res Treat
29217530The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). (2018 Mar 1)Aisner DLClin Cancer Res